SCHEMBL3758946

SCHEMBL3758946

CN(C)c1cccc(-c2cccc(-c3c(N4CCOCC4)sc4c3CC(C)(C)CC4=O)c2)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
CTDSP1 Q9GZU7 1/20 0.44
PIK3CD O00329 4/20 0.39
PIK3CA P42336 3/20 0.39
PIK3CB P42338 3/20 0.39
PIK3CG P48736 3/20 0.39
BRD4 O60885 1/20 0.38
GABRG2 P18507 3/20 0.36
GABRB3 P28472 3/20 0.36
GABRA5 P31644 3/20 0.36
GABRA1 P14867 2/20 0.36
GABRA3 P34903 2/20 0.36
GABRA2 P47869 2/20 0.36
MAPT P10636 2/20 0.36
RAB9A P51151 1/20 0.36
PRKDC P78527 4/20 0.35
FYN P06241 1/20 0.33
HSD17B10 Q99714 1/20 0.33
ATR Q13535 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3769311 0.98 HTT (0.46) HTTSMN1; SMN2CTDSP1PIK3CDPIK3CA
SCHEMBL3759696 0.90 SMN1; SMN2 (0.41) HTTSMN1; SMN2CTDSP1PIK3CDPIK3CA
SCHEMBL3758948 0.89 PIK3CD (0.42) PIK3CDPIK3CAPIK3CBPIK3CGBRD4
SCHEMBL3751935 0.86 AOC3 (0.40) PIK3CDPIK3CAPIK3CBPIK3CGBRD4
SCHEMBL3757704 0.85 PIK3CD (0.42) PIK3CDPIK3CAPIK3CBPIK3CGBRD4
SCHEMBL3766771 0.85 GABRA1 (0.48) PIK3CDPIK3CAPIK3CBPIK3CGBRD4
SCHEMBL3764864 0.84 PIK3CA (0.42) PIK3CDPIK3CAPIK3CBPIK3CGBRD4
SCHEMBL3760569 0.84 PRKDC (0.46) SMN1; SMN2PIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL3759346 0.84 AOC3 (0.39) HTTSMN1; SMN2CTDSP1PIK3CDPIK3CA
SCHEMBL3765101 0.83 PIK3CA (0.38) SMN1; SMN2PIK3CDPIK3CAPIK3CBPIK3CG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2029570-B1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA SA (BE) 2014-10-15 EP disclosed
US-8324204-B2 Fused thiophene derivatives as kinase inhibitors UCB PHARMA SA (BE) 2012-12-04 US disclosed
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors UCB PHARMA S.A. (BE) 2010-12-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors PIKFYVE, PI4KA, PIK3CA HTT 1234/4885SMN1; SMN2 1864/4885CTDSP1 3461/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.